Gratwohl, A., Pfirrmann, M., Zander, A., Kroger, N., Beelen, D., Novotny, J., Nerl, C., Scheid, C., Spiekermann, K., Mayer, J., Sayer, H. G., Falge, C., Bunjes, D., Doehner, H., Ganser, A., Schmidt-Wolf, I., Schwerdtfeger, R., Baurmann, H., Kuse, R., Schmitz, N., Wehmeier, A., Fischer, J. Th, Ho, A. D., Wilhelm, M., Goebeler, M-E, Lindemann, H. W., Bormann, M., Hertenstein, B., Schlimok, G., Baerlocher, G. M., Aul, C., Pfreundschuh, M., Fabian, M., Staib, P., Edinger, M., Schatz, M., Fauser, A., Arnold, R., Kindler, T., Wulf, G., Rosselet, A., Hellmann, A., Schaefer, E., Pruemmer, O., Schenk, M., Hasford, J., Heimpel, H., Hossfeld, D. K., Kolb, H-J, Buesche, G., Haferlach, C., Schnittger, S., Mueller, M. C., Reiter, A., Berger, U., Saussele, S., Hochhaus, A. and Hehlmann, R. (2016). Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 30 (3). S. 562 - 570. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N = 166 patients) and best available drug treatment (group B; N = 261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high( P < 0.001) and non-high-risk disease (P = 0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P = 0.005) and free of drug treatment (56% vs 6%; P < 0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gratwohl, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfirrmann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zander, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroger, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beelen, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Novotny, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nerl, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spiekermann, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sayer, H. G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Falge, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bunjes, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Doehner, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ganser, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt-Wolf, I.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schwerdtfeger, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baurmann, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuse, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmitz, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wehmeier, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, J. ThUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ho, A. D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wilhelm, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goebeler, M-EUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lindemann, H. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bormann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hertenstein, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlimok, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baerlocher, G. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aul, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfreundschuh, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fabian, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Staib, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Edinger, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schatz, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fauser, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arnold, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kindler, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wulf, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rosselet, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hellmann, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaefer, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pruemmer, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schenk, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hasford, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heimpel, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hossfeld, D. K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolb, H-JUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buesche, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haferlach, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schnittger, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, M. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reiter, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Berger, U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Saussele, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hochhaus, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hehlmann, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-283166
DOI: 10.1038/leu.2015.281
Journal or Publication Title: Leukemia
Volume: 30
Number: 3
Page Range: S. 562 - 570
Date: 2016
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
BONE-MARROW-TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; HEMATOPOIETIC SCT; DOSE IMATINIB; SURVIVAL; INTERFERON; RECOMMENDATIONS; MANAGEMENT; SUPERIORMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/28316

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item